Figure 2.
Ruxolitinib-treated patients in COMFORT-I experienced a statistically significant increase in overall survival (OS) compared to placebo.
Reprinted with permission from Massachusetts Medical Society.18
Ruxolitinib-treated patients in COMFORT-I experienced a statistically significant increase in overall survival (OS) compared to placebo.
Reprinted with permission from Massachusetts Medical Society.18